Online citations, reference lists, and bibliographies.

Riluzole And Edaravone: A Tale Of Two Amyotrophic Lateral Sclerosis Drugs.

M. K. Jaiswal
Published 2019 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval under Phase I-III trials. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival. Recently, an antioxidant drug, edaravone, developed by Mitsubishi Tanabe Pharma was found to be effective in halting ALS progression during early stages. The newly approved drug edaravone is a force multiplier for ALS treatment. This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures. Moreover, we also discussed the pressing issues and challenges of ALS clinical trials and drug developments as well as future outlook.
This paper references
10.1038/psp.2013.41
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
H. Jones (2013)
10.1503/cmaj.081879
Legumes, lemons and streptomycin: A short history of the clinical trial
R. Collier (2009)
10.1016/j.neuron.2016.04.006
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs
Jie Jiang (2016)
10.1016/j.neuron.2013.12.009
Neuronal Matrix Metalloproteinase-9 Is a Determinant of Selective Neurodegeneration
A. Kaplan (2014)
10.1016/S1474-4422(18)30111-X
What if you knew the prognosis of your patients with ALS?
Hiroshi Mitsumoto (2018)
Role of pharmacokinetics and metabolism in drug discovery and development.
J. Lin (1997)
10.3389/978-2-88945-146-3
The Role of Mitochondria, Oxidative Stress and Altered Calcium Homeostasis in Amyotrophic Lateral Sclerosis: From Current Developments in the Laboratory to Clinical Treatments
Manoj Kumar Jaiswal (2017)
10.14573/ALTEX.2007.4.320
Animal experiments scrutinised: systematic reviews demonstrate poor human clinical and toxicological utility.
A. Knight (2007)
10.1080/17482960802195913
Scrutinizing enrollment in ALS clinical trials: Room for improvement?
R. Bedlack (2008)
10.1016/j.neuint.2015.07.024
Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress
M. Jami (2015)
10.1056/NEJM199403033300901
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
G. Bensimon (1994)
10.1080/14656566.2017.1319937
Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis
Hideyuki Sawada (2017)
Tuesdays with Morrie: An Old Man, a Young Man, and Life's Greatest Lesson
M. Albom (1997)
10.3109/21678421.2014.959024
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
K. Abe (2014)
10.1016/j.stemcr.2017.09.021
Generation of a Motor Nerve Organoid with Human Stem Cell-Derived Neurons
Jiro Kawada (2017)
10.1038/nrn1870
Astrocyte dysfunction in neurological disorders: a molecular perspective
G. Seifert (2006)
10.1371/journal.pbio.1000412
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
C. Kilkenny (2010)
10.1186/1471-2202-14-37
Improving basic and translational science by accounting for litter-to-litter variation in animal models
S. Lazic (2012)
10.1016/J.NBD.2006.12.015
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
M. Benatar (2007)
10.1080/21678421.2017.1361442
Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis
Fumihiro Takahashi (2017)
10.1021/jp110400t
OH radical scavenging activity of Edaravone: mechanism and kinetics.
A. Pérez-González (2011)
10.4103/1673-5374.206635
Therapeutic opportunities and challenges of induced pluripotent stem cells-derived motor neurons for treatment of amyotrophic lateral sclerosis and motor neuron disease
Manoj Kumar Jaiswal (2017)
10.3389/fncel.2013.00199
Calcium, mitochondria, and the pathogenesis of ALS: the good, the bad, and the ugly
M. K. Jaiswal (2013)
10.1016/S1474-4422(18)30054-1
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Ton Fang (2018)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
10.1186/2052-8426-2-26
Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: implications for motoneurons specific calcium dysregulation
M. K. Jaiswal (2014)
10.1124/mol.108.050831
Cu/Zn Superoxide Dismutase Typical for Familial Amyotrophic Lateral Sclerosis Increases the Vulnerability of Mitochondria and Perturbs Ca2+ Homeostasis in SOD1G93A Mice
M. K. Jaiswal (2009)
10.1080/14660820410019602
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
V. Meininger (2004)
10.1186/1471-2202-10-64
Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease
M. K. Jaiswal (2009)
10.1016/j.brainres.2013.10.013
C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS
Theo Hatzipetros (2014)
10.1038/507423A
Preclinical research: Make mouse studies work.
S. Perrin (2014)
10.1038/nrneurol.2011.147
How can we improve clinical trials in amyotrophic lateral sclerosis?
P. Gordon (2011)
10.1016/S1474-4422(14)70129-2
Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
H. Mitsumoto (2014)
10.1038/s41598-017-00993-0
Endothelial and Astrocytic Support by Human Bone Marrow Stem Cell Grafts into Symptomatic ALS Mice towards Blood-Spinal Cord Barrier Repair
S. Garbuzova-Davis (2017)
10.3389/fncel.2016.00219
Promise and Pitfalls of Mitochondrial Replacement for Prevention and Cure of Heritable Neurodegenerative Diseases Caused by Deleterious Mutations in Mitochondrial DNA
A. Paine (2016)
10.1523/JNEUROSCI.1457-16.2016
Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy
Krista J Spiller (2016)
10.1016/S1474-4422(17)30115-1
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
K. Abe (2017)
10.1212/WNL.0b013e31822dc7a5
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis
R. Miller (2011)
10.1016/j.jns.2005.02.006
Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS
T. Heiman-Patterson (2005)
10.1212/WNL.0b013e318232ab9b
ALS clinical trials
A. Chiò (2011)
10.3389/fncel.2016.00295
Riluzole But Not Melatonin Ameliorates Acute Motor Neuron Degeneration and Moderately Inhibits SOD1-Mediated Excitotoxicity Induced Disrupted Mitochondrial Ca2+ Signaling in Amyotrophic Lateral Sclerosis
Manoj Kumar Jaiswal (2017)
10.1016/S1474-4422(18)30089-9
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model
H. Westeneng (2018)
10.1016/S1474-4422(17)30289-2
Edaravone for treatment of early-stage ALS
J. Mora (2017)
10.1016/J.TIPS.2006.03.009
Targets in ALS: designing multidrug therapies.
M. T. Carrì (2006)
10.1093/hmg/ddt202
PGC-1α is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis.
Judith Eschbach (2013)
10.1001/ARCHNEUR.58.3.512
How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot.
L. Rowland (2001)
10.1016/0022-510X(94)90191-0
El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
B. Brooks (1994)
10.1016/S0022-510X(99)00210-5
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
J. Cedarbaum (1999)
10.1002/eji.201142048
The need for littermate controls.
R. Holmdahl (2012)
10.1016/j.jns.2010.10.011
Gender-based effect of statins on functional decline in amyotrophic lateral sclerosis
B. Nefussy (2011)
10.1080/13510002.1996.11747069
Antioxidant activity of 3-methyl-1-phenyl-2-pyrazolin-5-one.
Y. Yamamoto (1996)
10.1126/science.aat6775
Stephen Hawking (1942–2018)
J. Preskill (2018)



This paper is referenced by
10.1186/s13024-020-00373-9
From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline
Rajka Maria Liscic (2020)
10.3389/fphar.2020.01148
Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis
C. Volonté (2020)
10.1186/s40035-020-00209-y
Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?
Y. Furukawa (2020)
10.4103/1673-5374.270309
Novel small molecule TRVA242 targets neuromuscular junction in amyotrophic lateral sclerosis
Poulomee Bose (2020)
10.3390/ijms21103651
ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS
Roberta Bonafede (2020)
10.1016/j.phrs.2019.03.002
Novel function of VEGF‐B as an antioxidant and therapeutic implications
Rongyuan Chen (2019)
10.4103/am.am_48_19
Edaravone: A new hope for patients with amyotrophic lateral sclerosis
Shivangi Garg (2019)
10.1016/j.semcdb.2019.04.014
Functional microglia neurotransmitters in amyotrophic lateral sclerosis.
C. Volonté (2019)
10.1083/jcb.202002179
Mitochondria as intracellular signaling platforms in health and disease.
Jay X Tan (2020)
10.3390/ijms21113801
CRISPR/Cas9-Mediated Gene Correction to Understand ALS
Yeomin Yun (2020)
10.1016/j.ebiom.2020.102980
Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis
K. Amporndanai (2020)
10.1016/j.nbd.2019.104532
Modified age-dependent expression of NaV1.6 in an ALS model correlates with motor cortex excitability alterations
Luana Saba (2019)
10.1080/14656566.2020.1746270
Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis
R. Hergesheimer (2020)
10.3389/fphys.2020.00361
Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases
Saeideh Momtaz (2020)
10.1016/j.abb.2019.01.024
Dysregulated mitochondrial Ca2+ and ROS signaling in skeletal muscle of ALS mouse model.
J. Zhou (2019)
10.1007/s12035-020-02006-0
Mechanistic Insights of Astrocyte-Mediated Hyperactive Autophagy and Loss of Motor Neuron Function in SOD1L39R Linked Amyotrophic Lateral Sclerosis
Chetan Singh Rajpurohit (2020)
10.1002/jcb.29533
The new role of riluzole in the treatment of pancreatic cancer through the apoptosis and autophagy pathways.
Rulin Sun (2019)
10.1002/adhm.201901589
Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases.
Chiara Martinelli (2019)
10.1007/s11302-020-09692-4
The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice
D. Ly (2020)
10.3390/ijms20112616
Risk Factors and Emerging Therapies in Amyotrophic Lateral Sclerosis
Natalia Nowicka (2019)
10.3389/fncel.2019.00480
Viral Infections Exacerbate FUS-ALS Phenotypes in iPSC-Derived Spinal Neurons in a Virus Species-Specific Manner
Jessica Bellmann (2019)
10.3389/fnins.2020.00573
Exciting Complexity: The Role of Motor Circuit Elements in ALS Pathophysiology
Zeynep I. Gunes (2020)
10.1016/j.injury.2019.12.030
Riluzole protects against skeletal muscle ischaemia-reperfusion injury in a porcine model.
R. Li (2019)
10.1038/s41598-020-69845-8
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients
Qianqian Zeng (2020)
10.5772/intechopen.91921
Introduction to Novel Motor Neuron Disease
H. F. Sibat (2020)
10.1007/s12035-020-02059-1
Decreased Mitochondrial Function, Biogenesis, and Degradation in Peripheral Blood Mononuclear Cells from Amyotrophic Lateral Sclerosis Patients as a Potential Tool for Biomarker Research
Beatriz Grisolia Araujo (2020)
10.3390/microorganisms8050784
The Role of the Microbiota–Gut–Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases
Mark E. Obrenovich (2020)
10.7150/ijbs.38487
Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice
Q. Zhou (2020)
10.1159/000506259
Voice-Based Classification of Amyotrophic Lateral Sclerosis: Where Are We and Where Are We Going? A Systematic Review
Helder Elísio Evangelista Vieira (2019)
10.1007/s13760-020-01382-7
Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina
C. Quarracino (2020)
10.1007/s13760-020-01430-2
Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience
I. Ismail (2020)
10.1155/2019/3675627
Mesenchymal Stem Cells: A Potential Therapeutic Approach for Amyotrophic Lateral Sclerosis?
Agnese Gugliandolo (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar